Cuba's breakthroughs by the biopharmaceutical industry in the production of vaccines are the basis of Soberana 1 vaccine candidate, recognized the president of the BioCubaFarma business group, Eduardo Martinez.
In statements to the Granma newspaper, the scientist drew attention to the results of that sector in the last 30 years that paved the way for that drug against Covid-19 to be currently in the clinical trial phase.
Martinez explained that all the experience accumulated by Cuban institutions allowed to act quickly and to have that first vaccine candidate, in clinical evaluation in humans, and others in an advanced phase of preclinical studies.
The expert stated that before the end of 2020 it is very likely that the country will have at least two other vaccine candidates being assessed in human beings.
BioCubaFarma's president set out that by using different technological platforms, those drugs do not compete in terms of productive capacities, which would allow, in a short period of time, to have the quantities of vaccines necessary to immunize the whole Cuban population.
Martinez commented that, if achieved, the scientific entity would facilitate to make those medicines available to countries that require them and to position them at different ages.